Investment
Features
FeesSafety
Academy
More
Pluang+

Compare SPDR Gold Trust (GLD) vs Eli Lilly And Co (LLY) Price & Performance

SPDR Gold TrustTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

SPDR Gold Trust vs Eli Lilly And Co — how do they compare? SPDR Gold Trust trades at $404.2, while Eli Lilly And Co trades at $1,221.01 (market cap $1.08T). The key difference: Eli Lilly And Co pays a 0.57% dividend while SPDR Gold Trust pays none. Which is the better fit depends on your goals.

GLDLLY
52-Week High
$495.90$1.24K
52-Week Low
$305.27$639.43
Market Cap
$1.08T
Sector
Health
Enterprise Value
$1.13T
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

SPDR Gold Trust

GLD trades at $404.93, up 0.57% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent news highlights gold's strength amid cooling inflation and geopolitical tensions, with spot gold reaching multi-month highs. The ETF shows momentum but faces resistance near $405.

The outlook remains positive due to safe-haven demand and central bank buying, though high RSI suggests near-term consolidation risks. Upside potential exists toward $4,500, but investors should monitor inflation data and Fed policy for directional cues amid elevated volatility.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.

Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About SPDR Gold Trust

GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.

Read more on GLD

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY